June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Ultra Widefield Fluorescein Angiography (UWF FA) in Retinal Vein Occlusion: 5-Year Data using the Networc grid from the SCORE2 Trial
Author Affiliations & Notes
  • Mary K Wilda
    Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, Wisconsin, United States
  • Ellie Corkery
    Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, Wisconsin, United States
  • Barbara A Blodi
    Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, Wisconsin, United States
  • Michael S Ip
    Doheny Eye Institute, Los Angeles, California, United States
  • Ingrid U Scott
    Penn State College of Medicine, Hershey, Pennsylvania, United States
  • Paul VanVeldhuisen
    The Emmes Company LLC, Rockville, Maryland, United States
  • Neal Oden
    The Emmes Company LLC, Rockville, Maryland, United States
  • Footnotes
    Commercial Relationships   Mary Wilda None; Ellie Corkery None; Barbara Blodi None; Michael Ip Alimera, Allergan, Amgen, Apellis, Clearside, Novartis, OCURX, Regeneron, Code C (Consultant/Contractor), Biogen, Genentech, Iveric Bio, Cell Lineage Therapeutics, Regenxbio, Code F (Financial Support); Ingrid Scott None; Paul VanVeldhuisen None; Neal Oden None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 1776. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mary K Wilda, Ellie Corkery, Barbara A Blodi, Michael S Ip, Ingrid U Scott, Paul VanVeldhuisen, Neal Oden; Ultra Widefield Fluorescein Angiography (UWF FA) in Retinal Vein Occlusion: 5-Year Data using the Networc grid from the SCORE2 Trial. Invest. Ophthalmol. Vis. Sci. 2023;64(8):1776.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : SCORE2 was a National Eye Institute sponsored clinical trial that demonstrated non-inferiority between aflibercept and bevacizumab in patients with macular edema due to CRVO or HRVO. As a secondary outcome, a subset of patients underwent UWF FA. We assessed SCORE2 UWF FA images for changes in both retinal leakage and retinal nonperfusion measured over 5 years.

Methods : At baseline, 92 SCORE2 patients were imaged with UWF FA using Optos TX (Optos PLC Dunfermline, Scotland). Grading was performed at the Wisconsin Reading Center using the Networc grid; area measurements were performed using planimetry and corrected for peripheral warping.

Results : All patients had leakage at baseline and over 80% had persistent leakage over 5 years. The mean leakage area decreased significantly from baseline to month 6 from 34% of the retina within the Networc grid to 7% and stayed between 4-10% throughout 5 years. Non-perfusion was present in 64% of participants at baseline; the mean percentage of the non-perfusion area remained stable at 5 - 10% of the Networc grid at baseline and all follow-up visits. Utilizing the Networc grid, the highest percentage of retinal nonperfusion was found in the far temporal periphery (Zone 3) at all visits.

Conclusions : In SCORE2, anti-VEGF treatment was associated with a significantly decreased area of retinal leakage over 5 years; the area of retinal nonperfusion did not change. SCORE2 image analysis of UWF FA provided quantitative areas of leakage and nonperfusion in participants with macular edema and RVO. The longitudinal grading protocol allowed for a greater understanding of change in the area and region of retinal nonperfusion and leakage over 5 years.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×